Cancer of Unknown Primary (CUP) - This test is designed to assist clinicians to accurately identify the origin of metastases. In 3%-5% of all cancer patients, clinicians cannot identify the origin of a patients' tumor. This information is crucial for determining treatment type. Rosetta Genomics has developed a panel of microRNA biomarkers potentially able to identify approximately thirty cancers
"Our proprietary microRNA detection and quantitation technologies are at the heart of our sensitive diagnostic products," noted Amir Avniel, President and CEO of Rosetta Genomics." Using very small amounts of tissue samples or body fluids, we are able to detect microRNAs on the order of single molecules, as well as differentiate microRNAs with only a single nucleotide mismatch. We look forward to the launch of our first diagnostic products in 2008."
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs.
The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rose
|SOURCE Rosetta Genomics Ltd|
Copyright©2007 PR Newswire.
All rights reserved